Sanara Medtech Inc
NASDAQ:SMTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sanara Medtech Inc
NASDAQ:SMTI
|
US |
|
Riso Kyoiku Co Ltd
TSE:4714
|
JP |
|
A
|
Alphabet Inc
XETRA:ABEA
|
US |
|
Newpeak Metals Ltd
ASX:NPM
|
AU |
|
GoTo Gojek Tokopedia PT Tbk
IDX:GOTO
|
ID |
|
Amplitech Group Inc
NASDAQ:AMPG
|
US |
|
Karin Technology Holdings Ltd
SGX:K29
|
HK |
|
Toly Bread Co Ltd
SSE:603866
|
CN |
|
Triboo SpA
MIL:TB
|
IT |
Sanara Medtech Inc
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
Revenue: Full year 2025 net revenue was $103.1 million, up 19% year-over-year; Q4 net revenue was $27.5 million, up 5% YoY (13% YoY ex-$1.8M Hurricane-related BIASURGE sales in 2024).
Guidance: Reaffirmed full year 2026 net revenue guidance of $116.0 million to $121.0 million (growth of ~13%–17%); Q1 2026 revenue expected $26.7 million to $27.2 million (~14%–16% YoY).
Profitability: Full year gross margin expanded to 93% (≈200 bps improvement); adjusted EBITDA for full year 2025 was $17.0 million and Q4 adjusted EBITDA was $4.7 million.
Cash / Balance Sheet: Cash of $16.6 million and long-term debt of $46.0 million as of December 31, 2025; generated $6.8 million cash from operations in 2025 (vs. $24,000 used in 2024).
Commercial traction: Distributor network grew to >450 contracted distributors and sold into >1,450 health care facilities (up from >1,300 in 2024); Vizient innovative technology contract for BIASURGE provides access to ~1,800 facilities.
Portfolio & pipeline: Clinical evidence expanded (peer-reviewed studies for BIASURGE and ALLOCYTE Plus); OsStic (breakthrough-designated injectable bone bio-adhesive) on track for U.S. commercialization in Q1 2027.
Cost and one-offs: Q4 operating expenses rose to $24.6 million driven by a $1.8 million noncash IP impairment and $1.2 million higher R&D spend; Q4 net loss from continuing operations was $1.1 million, or $0.13 per diluted share.
